002437.SZ
誉衡药业
SZSE · Healthcare · C 制造业 · CN
CNY 3.94
−9.43%Year over year
Reported trailing growth
- Revenue
- -11.5%
- EBITDA
- —
- EBIT
- +55.2%
- EPS
- +72.5%
- Free cash flow
- -27.8%
- Operating cash flow
- -33.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.8%
- EBITDA
- +31.8%
- EBIT
- +52.1%
- Net income
- +77.0%
- EPS
- +77.3%
- Free cash flow
- +3.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026